modulator of VRAC current 1
Dernière mise à jour 28 Jun 2022
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Ask Patient
- Version audio
- Ajouter aux sources préférées sur Google
La MLC1 gene provides instructions for making a protein that is found primarily in the brain but also in the spleen and white blood cells (leukocytes). Within the brain, the MLC1 protein is found in astroglial cells, which are a specialized form of brain cells called glial cells. Glial cells protect and maintain other nerve cells (neurons). The MLC1 protein functions at junctions that connect neighboring astroglial cells. The role of the MLC1 protein at the cell junction is unknown, but research suggests that it may control the flow of fluids into cells or the strength of cells' attachment to one another (cell adhesion). Studies indicate that the MLC1 protein may be involved in transporting molecules across the blood-brain barrier and the brain-cerebrospinal fluid barrier. These barriers protect the brain's delicate nerve tissue by allowing only certain substances to pass into the brain.
Sélections vidéo pour GènesBibliothèque vidéo
Normal function
La MLC1 gene provides instructions for making a protein that is found primarily in the brain but also in the spleen and white blood cells (leukocytes). Within the brain, the MLC1 protein is found in astroglial cells, which are a specialized form of brain cells called glial cells. Glial cells protect and maintain other nerve cells (neurons). The MLC1 protein functions at junctions that connect neighboring astroglial cells. The role of the MLC1 protein at the cell junction is unknown, but research suggests that it may control the flow of fluids into cells or the strength of cells' attachment to one another (cell adhesion). Studies indicate that the MLC1 protein may be involved in transporting molecules across the blood-brain barrier and the brain-cerebrospinal fluid barrier. These barriers protect the brain's delicate nerve tissue by allowing only certain substances to pass into the brain.
Conditions referring to this gene or chromosome
Other names
KIAA0027
LVM
megalencephalic leukoencephalopathy with subcortical cysts 1 gene product
MLC
MLC1_HUMAN
VL
Related patient information and medicines

Patient information leaflet
Médicaments biologiques pour la polyarthrite rhumatoïde
Biological medicines are a newer type of medicine, used to ease the symptoms of arthrite rhumatoïde and reduce the damaging effect of the disease on the joints. They are usually prescribed when you have tried older medicines called disease-modifying antirheumatic drugs (DMARDs) and these have not worked so well. If a biological medicine is going.

Patient information leaflet
Médicaments antirhumatismaux modificateurs de la maladie
Médicaments antirhumatismaux modificateurs de la maladie (DMARDs) are medicines that are normally prescribed as soon as rheumatoid arthritis (RA) is diagnosed, in order to reduce damage to the joints. Rarely, they can have serious side-effects affecting the blood, liver, or kidneys. DMARDS are usually taken for the rest of your life. Because they are taken for a.

Patient information leaflet
Lichen plan
Lichen plan mainly causes an itchy skin rash. In some people it also affects other parts of the body such as the mouth, genitals, nails and hair. Most people get better in 6-12 months. Treatment, commonly with a steroid cream or ointment, often eases the itch and may reduce the rash until the condition clears. What is lichen planus. Lichen.

Medicine leaflet
Étancercept
About etanercept Type of medicine A cytokine modulator biological medicine Used for Rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis; juvenile idiopathic arthritis (a type of arthritis in children); plaque psoriasis Also called Benapali®; Enbrel®; Erelzi® Available as Subcutaneous injection Etanercept is a biological medicine used.

Patient information leaflet
Test de sueur
Sweat tests analyse the amount of salt left on the skin when a person sweats. This can help to diagnose cystic fibrosis. Note : the information below is a general guide only. The arrangements, and the way tests are performed, may vary between different hospitals. Always follow the instructions given by your doctor or local hospital. What is a.

Patient information leaflet
Œsophage de Barrett
Dans Barrett's oesophagus the cells that line the lower gorge (œsophage) are abnormal. The main cause is long-standing reflux of acid from the stomach into the oesophagus. People with Barrett's oesophagus have an increased risk of developing cancer of the oesophagus. The risk is small. It is named after the doctor who first described it. In.
Lectures complémentaires et références
- modulator of VRAC current 1; MedlinePlus, National Library of Medicine.
- Boor PK, de Groot K, Waisfisz Q, Kamphorst W, Oudejans CB, Powers JM, Pronk JC, Scheper GC, van der Knaap MS. MLC1: a novel protein in distal astroglial processes. J Neuropathol Exp Neurol. 2005 May;64(5):412-9. doi: 10.1093/jnen/64.5.412.
- Capdevila-Nortes X, Lopez-Hernandez T, Apaja PM, Lopez de Heredia M, Sirisi S, Callejo G, Arnedo T, Nunes V, Lukacs GL, Gasull X, Estevez R. Insights into MLC pathogenesis: GlialCAM is an MLC1 chaperone required for proper activation of volume-regulated anion currents. Hum Mol Genet. 2013 Nov 1;22(21):4405-16. doi: 10.1093/hmg/ddt290. Epub 2013 Jun 20.
- Ilja Boor PK, de Groot K, Mejaski-Bosnjak V, Brenner C, van der Knaap MS, Scheper GC, Pronk JC. Megalencephalic leukoencephalopathy with subcortical cysts: an update and extended mutation analysis of MLC1. Hum Mutat. 2006 Jun;27(6):505-12. doi: 10.1002/humu.20332.
- Lopez-Hernandez T, Sirisi S, Capdevila-Nortes X, Montolio M, Fernandez-Duenas V, Scheper GC, van der Knaap MS, Casquero P, Ciruela F, Ferrer I, Nunes V, Estevez R. Molecular mechanisms of MLC1 and GLIALCAM mutations in megalencephalic leukoencephalopathy with subcortical cysts. Hum Mol Genet. 2011 Aug 15;20(16):3266-77. doi: 10.1093/hmg/ddr238. Epub 2011 May 30.
- Montagna G, Teijido O, Eymard-Pierre E, Muraki K, Cohen B, Loizzo A, Grosso P, Tedeschi G, Palacin M, Boespflug-Tanguy O, Bertini E, Santorelli FM, Estevez R. Vacuolating megalencephalic leukoencephalopathy with subcortical cysts: functional studies of novel variants in MLC1. Hum Mutat. 2006 Mar;27(3):292. doi: 10.1002/humu.9407.
Partagez vos pensées ou expériences avec les autres dans notre communautés de patients.
Inscrivez-vous à la newsletter Patient
Votre dose hebdomadaire de conseils de santé clairs et fiables - rédigés pour vous aider à vous sentir informé, confiant et maître de la situation.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.

